Call for Abstract
Global Congress on Neuroendocrine Tumors: Radiation Medicine and Therapies, will be organized around the theme “Hope Grows Here fight Back Endocrine Cancer”
Neuroendocrine Tumors (NETs) 2016 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Neuroendocrine Tumors (NETs) 2016
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Cancer, also called malignancy, is an abnormal growth of cells. There are more than 100 types of cancer, including breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. Symptoms vary depending on the type. Cancer treatment may include chemotherapy, radiation, and/or surgery.
- Track 1-1Breast Cancer
- Track 1-2Brain Cancer
- Track 1-3Melonoma
- Track 1-4Cervical Cancer
- Track 1-5Skin Cancer
The pathophysiology of Neuroendocrine cancer is not completely defined. Alterations of several molecular factors have been associated with malignancy. A neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional hormone-producing endocrine cells and nerve cells. Neuroendocrine cells are found throughout the body in organs such as the lungs and gastrointestinal tract, including the stomach and intestines. They perform specific functions, such as regulating the air and blood flow through the lungs and controlling the speed at which food is moved through the gastrointestinal tract.
- Track 2-1Molecular Factor Alteration
- Track 2-2Growth Hormones
- Track 2-3Oncogenes
- Track 2-4Apoptotic
- Track 2-5Cell-Cycle Inhibitory Factors
- Track 2-6Radioactive Scan
A risk factor is anything that increases a person’s chance of developing a tumor. Although risk factors often influence the development of a neuroendocrine tumor, most do not directly cause it. Some people with several risk factors never develop a tumor, while others with no known risk factors do some risk factors are as disused Age, Gender, Race/Ethnicity, Family history, Immune system suppression, Arsenic exposure. Generally, the cause of NETs is unknown people who have one of the rare family syndromes have a higher risk of developing NETs.
- Track 3-1Multiple endocrine neoplasia type 1 (MEN 1)
- Track 3-2Acromegaly
- Track 3-3Radiation Exposure
- Track 3-4Neurofibromatosis type 1
- Track 3-5Having a Previous Benign
- Track 3-6Von Hippel-Lindau syndrome (VHL)
There are a number of different types of NETs. They are generally called after the organ or type of cell they develop in. NETs most often develop in the gut or pancreas. These tumours are sometimes grouped together and called gastroenteropancreatic neuroendocrine tumours or GEP NETs for short. NETs of the gut are most often carcinoid tumours. They may also just be called carcinoid. NETs that develop in the pancreas are also called endocrine tumours of the pancreas. Some of these tumours can also develop outside the pancreas. For example, gastrinomas have been reported in the medical literature to develop in the ovaries, kidneys, stomach and liver, and not just in the pancreas and small bowel area.
- Track 4-1Insulinomas, VIPomas( vasoactive intestinal peptide), Somatostatinoma
- Track 4-2Endocrine tumors
- Track 4-3Carcinoid tumors
- Track 4-4Islet cell tumors.
- Track 4-5Adrenal glands – usually called adrenomedullary NETs
- Track 4-6Parathyroid gland – small glands attached to the thyroid gland
- Track 4-7Pituitary gland – a small gland in the brain
- Track 4-8Skin – Merkel cell cancer
- Track 4-9Thyroid Cancer – medullary thyroid tumours
- Track 4-10Thymoma and Thymic carcinoma
Staging is the process of finding out if and how far a cancer has spread. The stage of a cancer is one of the most important factors in choosing treatment options and predicting your chance for cure. Staging is based on the results of the physical exam, biopsy, and imaging tests (ultrasound, radioiodine scan, CT scan, MRI, chest x-ray, and/or PET scans). A staging system is a standard way to sum up how large a cancer is and how far it has spread. There is no standard staging system for a neuroendocrine tumor. The stages used to describe a pancreatic neuroendocrine tumor are the same as the stages for pancreatic cancer.
- Track 5-1Small and Large bowel NETs
- Track 5-2Appendiceal NETs
- Track 5-3Pancreatic NETs
- Track 5-4gastric NETs and lung NETs.
There are many ways to diagnose a tumor, determine whether it is cancerous, and if so, find out if it has spread to another part of the body, called metastasis. Some tests may also determine which treatments may be the most effective. For most types of tumors, a biopsy is the only way to make a definitive diagnosis of cancer. If a biopsy is not possible, the doctor may suggest other tests that will help make a diagnosis. Imaging tests may be used to find out whether a cancerous tumor has spread. This list describes options for diagnosing this type of tumor, and not all tests listed will be used for every person. Your doctor may consider these factors when choosing a diagnostic test: Age and medical condition, Type of tumor suspected, Signs and symptoms, Previous test results
- Track 6-1Blood/urine tests
- Track 6-2Laryngoscopy
- Track 6-3Computed tomography (CT or CAT) scan
- Track 6-4Surgical biopsy
- Track 6-5Computerised Tomography (CT) Scan
- Track 6-6Magnetic Imaging Resonance (MIR) Scan
Doctors are working to learn more about neuroendocrine tumors, how to best treat them, and how to provide the best care to people diagnosed with this disease. The following areas of research may include new options for patients through clinical trials. Always talk with your doctor about the diagnostic and treatment options best for you.
- Track 7-1chemotherapy and drug combinations
- Track 7-2Targeted therapy and combined treatments
- Track 7-3Radioactive Iodine (RAI) Therapy
- Track 7-4Chemotherapy
- Track 7-5External Beam Radiation Therapy
- Track 7-6Hormone Therapy
- Track 7-7Targeted Therapy for PNET and ENET
- Track 7-8From somatostatin to Lanreotide
Surgery is the main treatment in nearly every case of cancer, and it is the main treatment for both pheochromocytoma and Merkel cell cancer. During surgery, the doctor removes the tumor along with a small border of healthy tissue around the tumor, called a margin For pheochromocytoma, laparoscopic surgery may be performed. Laparoscopic surgery is a less invasive type of surgery that uses three or four small incisions instead of one large incision. A thin, lighted tube called a laparoscope that is attached to a video camera is inserted through one opening to guide the surgeon. Surgical instruments are inserted through the other openings to perform the surgery. If removing the tumor using surgery is not possible, it is called an inoperable tumor, and the doctor will recommend another type of treatment.
- Track 8-1Types of conventional surgery
- Track 8-2Debulking Surgery
- Track 8-3laparoscopic surgery in Neuroendocrine cancer
- Track 8-4Robotic Neuroendocrine Surgery
Genetic blood tests can be used to identify people who have a high risk of developing the familial types of Neuroendocrine Cancer. When inherited it strikes one family member, all family members can be tested. Those who test positive but have no symptoms of cancer may decide to have their early treatment to prevent the disease. At times when the particular hormone producing gland is removed after surgery, these patients need to take hormones substituents for the rest of their lives.
- Track 9-1Medication
- Track 9-2Screening
- Track 9-3Health History
- Track 9-4Surgery To Prevent Cancer
Doctors and scientists are always looking for better ways to treat patients with a neuroendocrine tumor. To make scientific advances, doctors create research studies involving volunteers, called clinical trials. Many clinical trials are focused on new treatments, evaluating whether a new treatment is safe, effective, and possibly better than the current (standard) treatment. These types of studies evaluate new drugs, different combinations of existing treatments, new approaches to radiation therapy or surgery, and new methods of treatment. Patients who participate in clinical trials are often among the first to receive new treatments before they are widely available. However, there is no guarantee that the new treatment will be safe, effective, or better than a standard treatment.There are also clinical trials that study new ways to ease symptoms and side effects during treatment and managing the late effects that may occur after treatment. Talk with your doctor about clinical trials regarding side effects.
- Track 10-1Neuroendocrine Cancer Surgery
- Track 10-2Neuroendocrine Cancer Radiation therapy
- Track 10-3Neuroendocrine Cancer Chemotherapy
- Track 10-4symptoms and side effects
- Track 10-5Remission and the chance of recurrence
- Track 10-6Company Coverage
Radiation Medicine is a process in wich they use high-energy radiation, in the form of waves or particles, to destroy cancer cells by damaging their DNA. Because radiation can harm healthy cells, treatment must be carefully planned and precisely conducted to minimize side effects. Radiation therapy may be given before, during, or after other therapies in your treatment plan. It may be used alone or with other treatments to destroy cancer cells, shrink tumors, prevent recurrence and relieve symptoms caused by the cancer, such as pain. The Radiation team plans the treatment by choosing the type, dose and area of radiation therapy to be performed. Radiation therapies include different delivery External radiation
- Track 11-1 External Beam Radiation Therapy (EBRT)
- Track 11-23-Dimensional Conformal Radiation Therapy (3D-CRT)
- Track 11-3Intensity Modulated Radiation Therapy (IMRT)
- Track 11-4Image-Guided Radiation Therapy (IGRT)
- Track 11-5Gamma Knife Radiosurgery
- Track 11-6Stereotactic Body Radiation Therapy (SBRT)
- Track 11-7Volumetric Modulated Arc Therapy (VMAT)
Radiation Medicine is a process in wich they use high-energy radiation, in the form of waves or particles, to destroy cancer cells by damaging their DNA. Because radiation can harm healthy cells, treatment must be carefully planned and precisely conducted to minimize side effects. Radiation therapy may be given before, during, or after other therapies in your treatment plan. It may be used alone or with other treatments to destroy cancer cells, shrink tumors, prevent recurrence and relieve symptoms caused by the cancer, such as pain. The Radiation team plans the treatment by choosing the type, dose and area of radiation therapy to be performed. Internal radiation(these include different radioactive material like seeds, beads, wires or other radioactive substances for the treatment by placing them within the body near the cancer cells. People involved in radiation medicine are Medical Physicist, Radiation Oncologist, Dosimetrist, Radiation Therapist.
- Track 12-1Brachytherapy
- Track 12-2Intraoperative Radiation Therapy
- Track 12-3Systemic Radiation Therapy
- Track 12-4Selective Internal Radiation Therapy (SIRT)
Nuclear medicine imaging uses small amounts of radioactive materials called radiotracers that are typically injected into the blood stream, inhaled or swallowed. The radiotracer travels through the area being examined and gives off energy in the form of gamma rays which are detected by a special camera and a computer to create images of the inside of your body. Nuclear medicine imaging provides unique information that often cannot be obtained using other imaging procedures and offers the potential to identify disease in its earliest stages.
- Track 13-1Standards
- Track 13-2Diagnostic Nuclear Medicine
- Track 13-3Therapeutic Nuclear Medicine
- Track 13-4Biomedical Research
Significant increase in funding for treatment of cancer by various international organizations such as American Cancer Academy and world Health Organization is expected to boost overall neuroendocrine carcinoma treatment market. Furthermore, significant increase in healthcare spending along with high prevalence rate of neuroendocrine carcinoma in developing region is expected to boost overall neuroendocrine carcinoma market. Though market is expected to witness healthy growth, lack of skilled healthcare professional and lower adoption of advanced treatment technologies in the developing economies are key restrains for neuroendocrine carcinoma market.
- Track 14-1Neuroendocrine Cancer Market: Segmentation
- Track 14-2Neuroendocrine Cancer Market: Overview
- Track 14-3Neuroendocrine Cancer Market: Region- wise Outlook